Overview

Carisma Therapeutics is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

05 Sep '23
PHILADELPHIA , Sept. 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) (" Carisma " or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present at several upcoming investor

Events

Corporate Presentation